Login to Your Account



CHASING RITUXAN'S MARKET

MMRGlobal lays IP groundwork in Asia

By Cornelia Zou
Staff Writer

Wednesday, February 19, 2014

HONG KONG – Most of Favrille Inc.’s market value vanished in 2008 after the firm said it would cease development of its active immunotherapy Specifid, which missed its primary endpoint in a pivotal phase III study in non-Hodgkin’s lymphoma. Almost a year later, San Diego-based Favrille merged with MyMedical-Records.com. The company once best known for providing health care IT services is just now stepping up its push into the biotechnology space in Asia.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription